Amgen Mum On Repatha Sales; Outcomes Data Needed To Sway US Payers
This article was originally published in Scrip
Executive Summary
Amgen Inc.'s 2015 revenue of $21.66bn, up 8% from the prior year, met analyst consensus expectations, but one of the biggest questions of all was left unanswered: How many millions of dollars in sales of the PCSK9 inhibitor Repatha (evolocumab) has the company generated so far?
You may also be interested in...
1Q Earnings Preview: What To Expect From US, EU Big Hitters
The slow drip of pharma industry earnings announcements that began on April 19 with Roche and Johnson & Johnson will turn into a veritable stream over the next couple of weeks. Scrip takes a look at expectations around some of the main firms due to report.
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.
Ipsen Expands Its Rare Neurological Disease Pipeline With Skyhawk Deal
Deal Snapshot: Ipsen committed up to $1.8bn in upfront and milestone fees to develop novel treatments for rare neurological diseases with Skyhawk’s RNA-targeting small molecule platform.